ChromatinBio provides a bioinformatics platform that mines large functional‑genomics datasets to discover short enhancer elements and design custom synthetic promoters. These compact, patentable promoters deliver precise, high‑level, and condition‑ or cell‑type‑specific gene expression for applications in cell and gene therapy, biologics manufacturing, industrial biotechnology, and agricultural biotech.
Funding
Funding not disclosed
Founders
Product
Problem
Biotech developers often lack compact, high‑precision promoters that can drive strong, cell‑type‑specific or condition‑responsive gene expression. Existing viral or native promoters are either too large for vector capacity, lack specificity, or provide insufficient control, leading to suboptimal therapeutic efficacy, low protein yields, and extensive empirical screening.
Solution
ChromatinBio offers a bioinformatics‑driven platform that mines large functional‑genomics datasets to identify short enhancer elements and design custom synthetic promoters. By combining these motifs, the platform creates compact, patentable promoters tailored to specific cell types, organisms, or environmental stimuli. The resulting gene expression vectors provide precise, high‑level, and controllable transcription suitable for cell and gene therapies, biologics manufacturing, industrial biotech, and agricultural applications. Clients receive custom promoter designs that meet defined activity profiles, enabling faster development cycles and improved product performance.
Target Audience
Primary customers are biotech companies developing cell and gene therapies, biologics manufacturers, industrial synthetic‑biology firms, and agricultural biotechnology developers seeking precise gene expression control.
Features
- Algorithmic analysis of multi‑omics data to isolate cell‑selective and condition‑responsive enhancer motifs
- Design of short synthetic promoters optimized for vector size constraints and high transcriptional strength
- Customizable promoter libraries for diverse chassis organisms (e.g., CHO cells, yeast, plant species) and tissue‑specific expression
- Ability to generate promoters with graded activity levels for multi‑gene pathway balancing and genetic circuit construction
- Patent‑eligible, unique sequence combinations ensuring intellectual‑property protection for client products
- Flexible delivery model including technology access fees and milestone‑based development contracts